

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. – 23. (Cancelled)

24. (Currently Amended) A method of treatment for arteriosclerosis, comprising administering to a mammal in need of treatment a medicament comprising ~~an acyclic polyprenyl compound~~ (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient such that ~~[[the]]~~ activation of a transcription factor KLF5 is inhibited and/or such that vascular remodeling is inhibited.

25. – 27. (Cancelled)

28. (Currently Amended) The method according to claim 37, wherein the composition is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive together with ~~an acyclic polyprenyl compound~~ the (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.

29. (Currently Amended) The method according to claim 37, wherein the composition is in the form of a pharmaceutical composition for oral administration.

30. – 31. (Cancelled)

32. (Currently Amended) The method according to claim 37, wherein the mammal is a human.

33. (Currently Amended) A method of inhibiting activation of a transcription factor KLF5, comprising:

contacting one or more cells which express KLF5 with a composition comprising an ~~an aeyelic polyprenyl compound~~ (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient such that [[the]] activation of KLF5 is inhibited.

34. - 36. (Cancelled)

37. (Currently Amended) A method of inhibiting vascular remodeling, comprising:  
administering to a mammal a composition comprising an ~~an aeyelic polyprenyl compound~~ (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient such that vascular remodeling is inhibited.

38. - 48. (Canceled)